NAT2 polymorphism associated with plasma glucose concentration in Canadian Oji-Cree

Pharmacogenetics

Volumn 10, Issue 3, 2000, Pages 233-238

  Hegele, Robert A ^a   Kwan, Kenneth ^a   Harris, Stewart B ^b   Hanley, Anthony J G ^c   Zinman, Bernard ^c   Cao, Henian ^a  

^a ROBARTS RESEARCH INSTITUTE   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

Author keywords

Diabetes; Metabolism; Native Canadians

Indexed keywords

ACYLTRANSFERASE; GLUCOSE; INSULIN; ORAL ANTIDIABETIC AGENT;

ADOLESCENT; ADULT; AGED; ALLELE; ARTICLE; CANADA; CHROMOSOME 22Q; CHROMOSOME 8P; CONTROLLED STUDY; ETHNIC GROUP; FEMALE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENOTYPE; GLUCOSE BLOOD LEVEL; HETEROZYGOTE; HOMOZYGOTE; HUMAN; HUMAN CELL; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PHENOTYPE; PRIORITY JOURNAL; SCHOOL CHILD;

EID: 0034091649     PISSN: 0960314X     EISSN: None     Source Type: Journal    
DOI: 10.1097/00008571-200004000-00004     Document Type: Article

References (21)

1. Cascorbi I, Drakoulis N, Brockmöller J, Maurer A, Sperling K, Roots I. Arylamine N-acelyltransferase (NAT2) mutations and their allelic linkage in unrelated Caucasian individuals: correlation with phenotypic activity. Am J Hum Genet 1995; 57:581-592.
2. Daly AK, Brockmöller J, Broly F, Eichelbaum M, Evans WE. Gonzalez FJ, et al. Nomenclature for human CYP2D6 alleles. Pharmacogenetics 1996; 6:193-201.
3. Elbein SC, Huffman MD, Bragg KL, Mayorga RA. The genetics of NIDDM. Diabetes Care 1994; 17:1523-1533.
4. Ghosh S, Schork NJ. Genetic analysis of NIDDM: the study of quantitative traits. Diabetes 1996; 45:1-14.
5. Gonzalez FJ. Cytochromes P450: metabolic and toxicological aspects: The CYP2D subfamily. Ioannides C, editor. London: CRC Press; 1996.
6. Gough AC, Smith CA, Howell SM, Wolf CR, Bryant SP, Spurr NK. Localization of the CYP2D gene locus to human chromosome 22q13.1 by polymerase chain reaction. in situ hybridization, and linkage analysis. Genomics 1993: 15:430-432.
7. Hanioka N, Kimura S, Meyer UA, Gonzalez FJ. The human CYP2D locus associated with a common genetic defect in drug oxidation: a G1934A base change in intron 3 of a mutant CYP2D6 allele results in an aberrant 3′ splice recognition site. Am J Hum Genet 1990; 47:994-1001.
8. Hanis CL, Boerwinkle E, Chakraborty R, Ellsworth DL, Concannon P, Stirling B, et al. A genome-wide search for human non-insulin-dependent (type 2) diabetes genes reveals a major susceptibility locus on chromosome 2. Nature Genet 1996; 13:161-166.
9. Harris SB, Gittelsohn J, Hanley AJG, Barnie A, Wolever TMS, Gao J, et al. The prevalence of NIDDM and associated risk factors in native Canadians. Diabetes Care 1997; 20:185-197.
10. Hegele RA, Brunt JH, Connelly PW. Multiple genetic determination of variation in plasma lipoproteins in a genetic isolate. Arterioscler Thromb Vasc Biol 1995; 15:861-871.
11. Hegele RA, Connelly PW, Scherer SW, Hanley AJ, Harris SB, Tsui LC, Zinman B. Paraoxonase-2 gene (PON2) G148 variant associated with elevated fasting plasma glucose in noninsulin-dependent diabetes mellitus. J Clin Indocrinol Metab 1997; 82:3373-3377.
12. Hegele RA, Sun F, Harris SB, Anderson C, Hanley AJ, Zinman B. Genome-wide scanning for type 2 diabetes susceptibility in Canadian Oji-Cree, using 190 microsatellite markers. J Hum Genet 1999; 44:10-14.
13. Hill WG, Robertson A. Linkage disequilibrium in finite populations. Theor Appl Genet 1968; 38:226-231.
14. Lander ES, Schork NJ. Genetics of complex traits. Science 1994; 265:2037-2048.
15. Mahtani MM, Widen E, Lehto M, Thomas J, McCarthy M, Brayer J, et al. Mapping of a gene for type 2 diabetes associated with an insulin secretion defect by a genome scan in Finnish families. Nature Genet 1996; 14:90-94.
16. Matas N, Thygesen P, Stacey M, Risch A, Sim E. Mapping AAC1, AAC2 and AACP, the genes for arylamine N-acetyltransferases, carcinogen metabolising enzymes on human chromosome 8p22, a region frequently deleted in tumours. Cytogenet Cell Genet 1997; 77:290-295.
17. Meyer UA, Zanger UM. Molecular mechanisms of genetic polymorphisms of drug metabolism. Annu Rev Pharmacol Toxicol 1997; 37:269-296.
18. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979; 28:1039-1057.
19. Nowak MP, Tyndale RF, Sellers EM. CYP2D6 phenotype and genotype in a Canadian native indian population. Pharmacogenetics 1997; 7:145-148.
20. SAS Institute Inc. SAS/STAT Guide for personal computers, version 6. Cary, NC: SAS Institute Inc; 1995.
21. WHO World Health Organization. (WHO) Expert Committee on Diabetes Mellitus. Second report. Technical report series 646. Geneva: WHO; 1980.